Atea Pharmaceuticals (AVIR) Prepaid Assets (2019 - 2026)
Atea Pharmaceuticals (AVIR) posted quarterly Prepaid Assets of $7.2 million for Q1 2026, down 13.07% year-over-year from $8.3 million in Q1 2025, and down 21.5% quarter-over-quarter from $9.2 million in Q4 2025.
Analysis
Atea Pharmaceuticals (AVIR) Prepaid Assets (2019 - 2026) Analysis & Trends
Atea Pharmaceuticals' Prepaid Assets history runs 8 years deep, the most recent figure standing at $7.2 million for Q1 2026.
- In Q1 2026, Prepaid Assets fell 13.07% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $7.2 million (down 13.07% YoY), while the FY2025 annual figure was $9.2 million, up 20.0% from the prior year.
- Prepaid Assets for Q1 2026 stood at $7.2 million, down from $9.2 million in the prior quarter.
- The five-year high for Prepaid Assets was $14.2 million in Q4 2022, with the low at $4.1 million in Q3 2024.
- The 5-year median for Prepaid Assets is $7.7 million (2022), against an average of $8.5 million.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets surged 278.76% in 2022, then tumbled 67.45% in 2024.
- Atea Pharmaceuticals' Prepaid Assets stood at $14.2 million in 2022, then retreated by 13.11% to $12.3 million in 2023, then plunged by 38.18% to $7.6 million in 2024, then grew by 20.0% to $9.2 million in 2025, then dropped by 21.5% to $7.2 million in 2026.
- Business Quant data shows AVIR's Prepaid Assets at $7.2 million in Q1 2026, $9.2 million in Q4 2025, and $6.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Atea Pharmaceuticals | 467.50 Mn | 467.50 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.20 Mn |
| Mar 31, 2026 | 7.19 Mn |
| Dec 31, 2025 | 9.16 Mn |
| Sep 30, 2025 | 6.83 Mn |
| Jun 30, 2025 | 5.89 Mn |
| Mar 31, 2025 | 8.27 Mn |
| Dec 31, 2024 | 7.63 Mn |
| Sep 30, 2024 | 4.09 Mn |
| Jun 30, 2024 | 4.16 Mn |
| Mar 31, 2024 | 7.27 Mn |
| Dec 31, 2023 | 12.35 Mn |
| Sep 30, 2023 | 8.19 Mn |
| Jun 30, 2023 | 12.76 Mn |
| Mar 31, 2023 | 11.90 Mn |
| Dec 31, 2022 | 14.21 Mn |
| Sep 30, 2022 | 12.45 Mn |
| Jun 30, 2022 | 4.97 Mn |
| Mar 31, 2022 | 7.69 Mn |
| Dec 31, 2021 | 8.03 Mn |
| Sep 30, 2021 | 3.29 Mn |